Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma

<div>T2-FLAIR Magnetic Resonance Imaging (MRI) brain with contrast demonstrating (a) symmetric T2-hyperintensity of the cerebellum on initial case presentation, (b) representative image demonstrating lack of cerebral involvement during initial case presentation, (c) subsequent 2-week follow-up MRI demonstrating resolving T2-hyperintensity in the cerebellum, and (d) complete resolution of cerebellar T2-hyperintensity 6 months postpresentation.</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma 

Figure 2 | Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma 